Abstract
Although slow/no-reflow is a serious problem complicating primary percutaneous coronary interventions (PCI) for acute myocardial infarction (AMI) and is associated with a poor prognosis, its efficacious treatment remains problematic. We compared the acute, in-hospital and long-term (1 year) effects of nitroprusside (NTP) with those of nicorandil (NC) on the slow/no-reflow phenomenon. Forty-nine of 442 consecutive patients with AMI who underwent primary PCI complicated by slow/no-reflow and who received intracoronary NTP (n = 25) or NC (n = 24) administration were studied. Both NTP and NC induced significant improvements in coronary flow, with increases in TIMI flow grade from 1.64 ± 0.62 to 2.74 ± 0.36 (p < 0.001) and 1.60 ± 0.86 to 2.23 ± 0.91 (p < 0.001), and in corrected TIMI frame count from 37.8 ± 15.1 to 13.7 ± 7.1 (p < 0.001) and 30.8 ± 20.7 to 19.3 ± 17.9 (p < 0.001), respectively. The degree of improvement in TIMI flow grade (post–pre/pre) and TIMI frame count (pre–post/pre) showed that NTP was more effective than NC (NTP vs. NC: 0.88 ± 0.79, 0.37 ± 0.37, p = 0.008; 0.59 ± 0.23, 0.36 ± 0.27, p = 0.003, respectively). Congestive heart failure did not tend to last beyond 3 days after onset in the NTP group, which was more than in the NC group, during hospitalization (1/25, 4/24, p = 0.143, respectively). At the 1-year follow-up, the NTP group tended to show more improvement than the NC group in MACE (5/25, 9/24, p = 0.175, respectively). NTP is a more effective treatment for slow/no-reflow associated with PCI in patients with AMI and may improve long-term clinical outcomes compared with NC.
Similar content being viewed by others
References
Abbo KM, Dooris M, Glazier S, O’Neill WW, Byrd D, Grines CL, Safian RD (1995) Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 75:778–782
Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP, Kuntz RE, Baim DS (1994) Incidence and treatment of “no-reflow” after percutaneous coronary intervention. Circulation 89:2514–2518
Akdemir R, Karakurt O, Kilie H, Yesilay AB, Dogan M, Cagirci G, Acikel S, Akdemir N (2010) Effect of reperfusion therapy on index of myocardial performance in acute myocardial infarction: thrombolytics versus primary angioplasty. Heart Vessels 25:87–91
Feld H, Lichstein E, Schachter J, Shani J (1992) Early and late angiographic findings of the “no-reflow” phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 123:782–784
Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S (2002) Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J 66:1119–1123
Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, O’Neill W, Grines CL (2003) Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42:1739–1746
Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug J-E, Ruzyllo W, Urban P, Stone GW, Wijns W (2005) Guidelines for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26:804–847
Gibson CM, Cannon CP, Piana RN, Maher KA, Davis SF, Breall JA, for the TIMI 4 group (1992) Relationship of coronary flow to myocardial infarction size: two sample methods to subclassify TIMI flow grades. Circulation 86:I453
Gibson CM, Schomig A (2004) Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation 109:3096–3105
Sakata Y, Kodama K, Ishikura F, Komamura K, Hasegawa S, Sakata Y, Hirayama A (1997) Disappearance of the ‘no-reflow’ phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 61:455–458
Gibson CM, Cannon CP, Daley W, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E (1996) TIMI frame count. A quantitative method of assessing coronary artery flow. Circulation 93:879–888
Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T (1996) Clinical implications of the no reflow phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93:223–228
Lloyd-Jones DM, Bloch KD (1996) The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 47:365–375
Gavin JB, Maxwell L, Edgar SG (1998) Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 30:2531–2540
Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim N-H, Ahn YK, Jeong J-W (2009) Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome. Heart Vessels 24:175–180
Myers PR, Banitt PF, Guerra R Jr, Harrison DG (1989) Characteristics of canine coronary resistance arteries: importance of endothelium. Am J Physiol 257:H603–H610
Wang WZ, Anderson G, Fleming JT, Peter FW, Franken RJ, Acland RD, Barker J (1997) Lack of nitric oxide contributes to vasospasm during ischemia/reperfusion injury. Plast Reconstr Surg 99:1099–1108
Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR (2001) Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 37:1335–1343
Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS (2004) Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 63:171–176
Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G (2005) Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 95:1358–1361
Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, Setsuda M, Makino K, Yamakado T, Nakano T (2006) Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 70:1099–1104
Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T (1999) Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33:654–660
Jia X, Wei M, Fu X, Gu X, Fan W, Zhang J, Xue L (2009) Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. Heart Vessels 24:340–346
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobatake, R., Sato, T., Fujiwara, Y. et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 26, 379–384 (2011). https://doi.org/10.1007/s00380-010-0065-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-010-0065-5